Short Term Price Target on Horizon Pharma plc (HZNP)

Horizon Pharma plc (NASDAQ:HZNP) : Average target price received by Horizon Pharma plc (NASDAQ:HZNP) is $32.29 with an expected standard deviation of $8.46. The most aggressive target on the stock is $45, whereas the most downbeat target is $24. 7 financial analysts are currently covering the stock.

Horizon Pharma plc has lost 5.56% in the last five trading days and dropped 5.89% in the last 4 weeks. Horizon Pharma plc has dropped 5.18% during the last 3-month period . Year-to-Date the stock performance stands at -24%.

Horizon Pharma plc (NASDAQ:HZNP) has an average broker rating of 1.47, which is interpreted as a Strong Buy, as rated by 7 equity analysts. Nonetheless, 6 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. Ranking by Zacks Investment Research for Coach Inc is 3, which is also a Hold. 1 brokerage firm advices Strong Sell on the share due to lack of confidence about the future of the company.

Horizon Pharma plc (NASDAQ:HZNP): The stock opened at $16.94 on Thursday but the bulls could not build on the opening and the stock topped out at $17.00 for the day. The stock traded down to $16.25 during the day, due to lack of any buying support eventually closed down at $16.47 with a loss of -1.67% for the day. The stock had closed at $16.75 on the previous day. The total traded volume was 3,701,670 shares.

In an insider trading activity, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the director of Horizon Pharma Plc, Nohria Virinder had sold 25,000 shares worth of $442,250 in a transaction dated June 15, 2016. In this transaction, 25,000 shares were sold at $17.69 per share.

Horizon Pharma plc, formerly Vidara Therapeutics International Public Limited Company, is a specialty biopharmaceutical company focused on identifying, developing, acquiring or in-licensing and commercializing differentiated products that address unmet medical needs. The Company markets a portfolio of products in arthritis, inflammation and orphan diseases. The Companys the United States marketed products are ACTIMMUNE (interferon gamma-1b), DUEXIS (ibuprofen/famotidine), PENNSAID (diclofenac sodium topical solution) 2% w/w (PENNSAID 2%), RAYOS (prednisone) delayed-release tablets and VIMOVO (naproxen/esomeprazole magnesium). The Company developed DUEXIS and RAYOS/LODOTRA, has the United States rights to VIMOVO, has the United States rights to ACTIMMUNE and has the United States rights to PENNSAID 2%.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.